In plain English. Cited. Updated when the science updates.
GLP-1 receptor agonists suppress appetite and slow gastric emptying. The result is significant weight loss — and, without intervention, significant lean mass loss alongside the fat. Here's what the studies show, drug by drug.
The lean-mass-loss evidence across 8 published trials. The 25–40% figure, where it comes from, and what changes it.
Read article →Typical pattern across titration, peak dose, and maintenance. What is common, what is rare, when to call your healthcare provider.
Read article →2026 head-to-head: active ingredient, dosing, efficacy, side-effect profile, regional cost.
Read article →What it is, who prescribes it, what the evidence says about quality variation, and how to track it.
Read article →How the absorption-enhancer formulation works, the 30-minute fasting rule, and what the evidence says about the higher-dose Wegovy pill.
Read article →The good news: lean mass loss on a GLP-1 is largely preventable. Three levers — protein, resistance training, and avoiding extreme calorie deficits — drop muscle-loss share from 25–40% to under 10%. Here are the protocols, the evidence behind them, and what Muscle Guard tracks for you.
Where the range comes from, why the upper end matters most on a GLP-1, and the per-meal distribution that maximises muscle protein synthesis.
Read article →2 to 4 sessions per week, all major groups, RPE 7–9. The lift-by-lift architecture that holds the floor.
Read article →Can you build lean mass while losing fat? The realistic frame, the DEXA cadence, and what the data actually supports.
Read article →The verbatim search term, demystified. What's actually happening, what's preventable, what isn't.
Read article →Three regain patterns from the post-discontinuation data, the taper-versus-hard-stop decision, and the maintenance protocol.
Read article →Methodology, inputs, weights, and what "on track" looks like — the one number that captures fat-loss-without-muscle-loss.
Read article →A chronological log of every study, paper, and clinical analysis we've factored into the library. Updated monthly. If a new paper changes what we publish, we say so here first.
Reverse-chronological list of every study added to the library, with a one-sentence plain-English summary and a "what changed" tag if it altered existing content.
Read the log →Cost, access, medical aid, and the compounded-preparation landscape. ZAR-priced, SAHPRA-grounded.
Read article →The five-day prep window, the three questions to ask every consult, and what the doctor PDF turns into in 60 seconds of read time.
Read article →What the leading trackers do with your data, what GDPR/POPIA/CCPA actually require, and the questions to ask before you install.
Read article →Get new research articles when they ship. One email per week. No marketing, no third parties. Unsubscribe in one tap.
We'll never use the email for anything other than research updates. Read the Privacy Policy.